	US 11,981,710 B2
	N-terminal capping modules of ankyrin repeat domains
Johannes Schilling, Zurich-Schlieren (CH); and Patrik Forrer, Zurich-Schlieren (CH)
Assigned to Athebio AG, (CH)
Filed by ATHEBIO AG, Zurich-Schlieren (CH)
Filed on Jun. 28, 2022, as Appl. No. 17/851,959.
Application 17/851,959 is a continuation of application No. PCT/EP2021/072819, filed on Aug. 17, 2021.
Application PCT/EP2021/072819 is a continuation in part of application No. 17/232,470, filed on Apr. 16, 2021, granted, now 11,242,369, issued on Feb. 8, 2022.
Claims priority of application No. 20191632 (EP), filed on Aug. 18, 2020.
Prior Publication US 2022/0340625 A1, Oct. 27, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/47 (2006.01); A61K 38/17 (2006.01); A61K 47/02 (2006.01); C07K 19/00 (2006.01)

CPC C07K 14/47 (2013.01) [C07K 19/00 (2013.01); A61K 38/17 (2013.01); A61K 47/02 (2013.01); C07K 2317/76 (2013.01); C07K 2317/94 (2013.01); C07K 2319/35 (2013.01)]

13 Claims

1. A protein comprising an ankyrin repeat domain,

wherein said ankyrin repeat domain comprises an N-terminal capping module, and

wherein said N-terminal capping module has an amino acid residue selected from the group consisting of: I, A, V and M, at the position corresponding to position 15 of SEQ ID NO: 3;

wherein said N-terminal capping module further has an amino acid residue selected from the group consisting of: K, E, A and L, at the position corresponding to position 11 of SEQ ID NO: 3 and/or an amino acid residue selected from E and K at the position corresponding to position 19 of SEQ ID NO: 3; and

wherein said N-terminal capping module comprises an amino acid sequence that has at least 70% sequence identity with an amino acid sequence selected from the group consisting of SEQ ID NOs: 1 to 76.